APO-LEFLUNOMIDE leflunomide 20mg tablets bottle

Country: Ավստրալիա

language: անգլերեն

source: Department of Health (Therapeutic Goods Administration)

active_ingredient:

leflunomide, Quantity: 20 mg

MAH:

Arrotex Pharmaceuticals Pty Ltd

INN:

Leflunomide

pharmaceutical_form:

Tablet, uncoated

composition:

Excipient Ingredients: colloidal anhydrous silica; lactose; magnesium stearate; crospovidone

administration_route:

Oral

units_in_package:

30 tablets

prescription_type:

(S4) Prescription Only Medicine

therapeutic_indication:

Apo-Leflunomide is indicated for the treatment of active rheumatoid arthritis. The combined use of Apo-Leflunomide with other disease modifying antirheumatic drugs (DMARDs) has not been adequately studied (see Precautions).

leaflet_short:

Visual Identification: White, arc-triangular shaped tablet. Engraved "LE" over "20" on one side and "APO" on the other side.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

authorization_status:

Licence status A

authorization_date:

2011-07-22